Laboratory monitoring should continue for several weeks after discontinuation, particularly hemoglobin A1c and weight measurements, to assess metabolic trajectory and guide subsequent management
"They have done a lot of studies that it lowers the risk of cardiac disease, renal disease and obesity because there's not as much workload on the heart," Lockman said
Based on the structural mechanism studies of GLP-1, Tirzepatide, Danuglipron, LY3502970, and TT-OAD2 involved in GLP-1R receptor recognition, the binding pockets for Danuglipron, LY3502970, and TT-OAD2 are distinctly different: only three residues interact with all three compounds, thirteen residues interact with two of the three compounds, and twenty-two residues only interact with one of the compounds
A few formulations get around it with absorption enhancers or enteric coatings
Population-relevant exclusion criteria after manual review of the eligibility-criteria text of all 352 GLP-1 RA trials
Reach your goals with GLP-1s